Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07278986
EARLY_PHASE1

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

Sponsor: Abramson Cancer Center at Penn Medicine

View on ClinicalTrials.gov

Summary

The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.

Official title: Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Imaging of Patients With Endometrial Cancer Planned for Surgery

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-10-18

Completion Date

2029-02

Last Updated

2025-12-12

Healthy Volunteers

No

Interventions

DRUG

CYTALUX™ (pafolacianine)

CYTALUX™ (pafolacianine) injection and standard care laparoscopic evaluation of disease. Intraoperative imaging with Cytalux will be performed for assessment of disease detection in patients who are being evaluated to undergo surgery for endometrial cancer. Any tissues removed as part of standard of care will undergo assessment with NIR light imaging prior to and after resection. This will be then compared to gold standard histologic confirmation by pathology.

DEVICE

1788 4K Camera System with Advanced Imaging Modality

Combination Product

Locations (2)

Abramson Cancer Center at Penn Medicine

Philadelphia, Pennsylvania, United States

University of Pennsylvania Gynecologic Oncology Department

Philadelphia, Pennsylvania, United States